These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1497003)

  • 1. Impact and cost-effectiveness of smoking interventions.
    Tsevat J
    Am J Med; 1992 Jul; 93(1A):43S-47S. PubMed ID: 1497003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expected gains in life expectancy from various coronary heart disease risk factor modifications.
    Tsevat J; Weinstein MC; Williams LW; Tosteson AN; Goldman L
    Circulation; 1991 Apr; 83(4):1194-201. PubMed ID: 2013141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
    Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
    JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research.
    Cromwell J; Bartosch WJ; Fiore MC; Hasselblad V; Baker T
    JAMA; 1997 Dec; 278(21):1759-66. PubMed ID: 9388153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The SmokingPaST Framework: illustrating the impact of quit attempts, quit methods, and new smokers on smoking prevalence, years of life saved, medical costs saved, programming costs, cost effectiveness, and return on investment.
    O'Donnell MP; Roizen MF
    Am J Health Promot; 2011; 26(1):e11-23. PubMed ID: 21879928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects.
    Yudkin JS
    BMJ; 1993 May; 306(6888):1313-8. PubMed ID: 8518573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Life expectancy following dietary modification or smoking cessation. Estimating the benefits of a prudent lifestyle.
    Grover SA; Gray-Donald K; Joseph L; Abrahamowicz M; Coupal L
    Arch Intern Med; 1994 Aug; 154(15):1697-704. PubMed ID: 8042886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction.
    Hay JW; Wittels EH; Gotto AM
    Am J Cardiol; 1991 Apr; 67(9):789-96. PubMed ID: 1901436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation of quitting smoking in the military shows higher lifetime medical spending more than offset by productivity gains.
    Yang W; Dall TM; Zhang Y; Zhang S; Arday DR; Dorn PW; Jain A
    Health Aff (Millwood); 2012 Dec; 31(12):2717-26. PubMed ID: 23213156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The global impact of noncommunicable diseases: estimates and projections.
    Manton KG
    World Health Stat Q; 1988; 41(3-4):255-66. PubMed ID: 3232413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of a smoking cessation program in patients admitted for coronary heart disease.
    Quist-Paulsen P; Lydersen S; Bakke PS; Gallefoss F
    Eur J Cardiovasc Prev Rehabil; 2006 Apr; 13(2):274-80. PubMed ID: 16575284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Older adults and smoking.
    LaCroix AZ; Omenn GS
    Clin Geriatr Med; 1992 Feb; 8(1):69-87. PubMed ID: 1576581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvements in life expectancy among Australians due to reductions in smoking: Results from a risk percentiles approach.
    Mannan H; Curtis AJ; Forbes A; Magliano DJ; Lowthian JA; Gambhir M; McNeil JJ
    BMC Public Health; 2016 Jan; 16():77. PubMed ID: 26813029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Cigarette Smoking and Smoking Cessation on Life Expectancy Among People With HIV: A US-Based Modeling Study.
    Reddy KP; Parker RA; Losina E; Baggett TP; Paltiel AD; Rigotti NA; Weinstein MC; Freedberg KA; Walensky RP
    J Infect Dis; 2016 Dec; 214(11):1672-1681. PubMed ID: 27815384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cost-effectiveness of counseling smokers to quit.
    Cummings SR; Rubin SM; Oster G
    JAMA; 1989 Jan; 261(1):75-9. PubMed ID: 2491762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gains in life expectancy in the Australian population due to reductions in smoking: comparisons between interventions targeting the population versus interventions in a specific high risk group.
    Mannan H
    BMC Public Health; 2020 Sep; 20(1):1478. PubMed ID: 32993598
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.